Literature DB >> 18489588

Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.

R Talpur1, R Bassett, M Duvic.   

Abstract

BACKGROUND: Mycosis fungoides (MF) and Sézary syndrome (SS), variants of cutaneous T-cell lymphoma, may arise from antigen-driven clonal expansion and accumulation of helper-memory T cells. Superantigens from Staphylococcus aureus can stimulate T cells.
OBJECTIVES: (i) To determine the prevalence of S. aureus carriage in nares and skin in patients with MF/SS compared with historical rates in other conditions. (ii) To determine whether eradication of S. aureus carriage is associated with clinical improvement. Methods Skin and nares cultures were performed prospectively. Patients with positive nares and skin cultures were treated with oral antibiotics and intranasal mupirocin 2% and samples were taken for reculturing at 3 days, 4 weeks and 8 weeks. An exact binomial test was used to compare the carriage rates among different groups.
RESULTS: Among 106 patients with MF/SS, 67 (63%) had skin colonization and 57 (54%) had nasal colonization. Staphylococcus aureus was isolated from 44 patients, 33 (31%) each from skin and nares. Colonization was highest in erythrodermic SS (48%), similar to atopic dermatitis (64%), and lowest in MF without erythroderma (26%), psoriasis (21%), and the general population (10%). Oral and topical antibiotics eradicated S. aureus colonization in nares in 28 of 33 (85%) patients and in MF skin lesions in 30 of 33 (91%) patients at 4-8 weeks, with rapid clinical improvement seen in 58% of S. aureus-colonized patients.
CONCLUSIONS: Staphylococcal carriage in nares and skin lesions of patients with MF is similar to that in atopic dermatitis. Eradication of staphylococci from the skin is possible with treatment and was associated with clinical improvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489588     DOI: 10.1111/j.1365-2133.2008.08612.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  44 in total

1.  Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Authors:  Pamela B Allen; Jeffrey Switchenko; Amy Ayers; Esther Kim; Mary Jo Lechowicz
Journal:  Leuk Lymphoma       Date:  2020-06-19

2.  Nasal vestibulitis due to targeted therapies in cancer patients.

Authors:  Janelle N Ruiz; Viswanath Reddy Belum; Christine B Boers-Doets; Mini Kamboj; N Esther Babady; Yi-Wei Tang; Tulio A Valdez; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2015-01-22       Impact factor: 3.603

3.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

4.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

Review 5.  Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.

Authors:  Madeleine Duvic; Mark Evans; Casey Wang
Journal:  Ther Adv Hematol       Date:  2016-03-17

6.  Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.

Authors:  Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov
Journal:  J Invest Dermatol       Date:  2017-11-08       Impact factor: 8.551

7.  Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis.

Authors:  B O Dulmage; H Feng; E Mirvish; L Geskin
Journal:  Br J Dermatol       Date:  2015-03-08       Impact factor: 9.302

8.  Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.

Authors:  Lise M Lindahl; Andreas Willerslev-Olsen; Lise M R Gjerdrum; Pia R Nielsen; Edda Blümel; Anne H Rittig; Pamela Celis; Bjorn Herpers; Jürgen C Becker; Birgitte Stausbøl-Grøn; Mariusz A Wasik; Maria Gluud; Simon Fredholm; Terkild B Buus; Claus Johansen; Claudia Nastasi; Lukas Peiffer; Linda Kubat; Michael Bzorek; Jens O Eriksen; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Carsten Geisler; Tomas Mustelin; Erik Langhoff; Michael Givskov; Anders Woetmann; Mogens Kilian; Thomas Litman; Lars Iversen; Niels Odum
Journal:  Blood       Date:  2019-07-22       Impact factor: 22.113

Review 9.  Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy.

Authors:  Ivan V Litvinov; Anna Shtreis; Kenneth Kobayashi; Steven Glassman; Matthew Tsang; Anders Woetmann; Denis Sasseville; Niels Ødum; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2016-06-06       Impact factor: 8.110

10.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.